Peregrine Pharma (PPHM) recently announced that the US. Food and Drug Administration (FDA) has approved on the design for their Phase III registration trial for its oncology drug, Bavituximab.
Browsing: bavituximab
Peregrine Pharmaceuticals reported positive Phase II data in a clinical trial of bavituximab in patients with a deadly form of lung cancer.